ClinicalTrials.gg
CompletedNCT01911780Updated Mar 28, 2016Results posted

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine

A Phase 3 interventional study of placebo and telmisartan + HCTZ in Hypertension, sponsored by Boehringer Ingelheim. Completed at 17 sites in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
112th of 186
132 · median 180
Started
2013
with 6 others
Phase 3
69 of 187
2 open now
Registered
113th of 187
by date
Lead sponsor
12 of 187
Boehringer Ingelheim

Among the 187 studies testing amlodipine in Hypertension, this one is the 112th largest by enrollment of the 186 interventional ones that give a count, is one of 7 that started in 2013, is one of 69 in phase 3, and was the 113th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.

Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/H12.5 mg.

In addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period.

In the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5 mg group change to the T80/A5/H12.5 mg therapy.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be >=90 and \<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\<200 mmHg
  2. Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion
  3. Age 20 years or older

Exclusion criteria

Exclusion criteria:

  1. Patients with known or suspected secondary hypertension
  2. Patients with cardiac arrhythmia
  3. Congestive heart failure with (NYHA) functional class III-IV
  4. Patients with recent cardiovascular events
  5. Patients with recent stroke events
  6. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy
  7. Patients with hepatic and/or renal dysfunction
  8. Pre-menopausal women who are nursing or pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
132 participants (actual)

Study arms

  • Experimental
    telmisartan + HCTZ + amlodipine

    telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)

    Drug: telmisartan + HCTZ · Drug: amlodipine

  • Active comparator
    telmisartan + HCTZ + placebo

    telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)

    Drug: placebo · Drug: telmisartan + HCTZ

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.

    Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: baseline and 8 weeks

Secondary outcomes

  1. Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.

    Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: baseline and 8 weeks

  2. The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.

    The percentage of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: Double-blind and 8 weeks

  3. The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.

    The number of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: Reference baseline (week 0) and week 60 (end of extension period)

  4. Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.

    Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: Reference baseline (week 0) and week 60 (end of extension period)

  5. Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.

    Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

    Time frame: Reference baseline (week 0) and week 60 (end of extension period)

07

Results

Posted Mar 28, 2016

Participant flow

Of the 239 enrolled patients, 205 patients were entered in the run-in period and 132 were randomized. The remaining 107 patients were withdrawn from the trial before the randomization.

Double-blind Period (8 Weeks)
Participant flow — Double-blind Period (8 Weeks)
MilestoneTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
Started6864
Completed6561
Not completed33
Withdrew: Adverse event12
Withdrew: Consent withdrawn not due to aes11
Withdrew: Personal reason10
Extension Period (52 Weeks)
Participant flow — Extension Period (52 Weeks)
MilestoneTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
Started6561
Completed6158
Not completed43
Withdrew: Adverse event30
Withdrew: Consent withdrawn not due to aes02
Withdrew: Personal reason11

Outcome measures

PrimaryChange From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.

Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
mmHgTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.-8.8 ± 0.8-1.3 ± 0.8
Statistical analysis
  • Telmisartan + HCTZ + Amlodipine vs Telmisartan + HCTZ + Placebo · LOCF-ANCOVA · p = <0.0001 · Adjusted mean, comparison: -7.5 · 95% CI -9.7 to -5.3Model includes baseline DBP as a linear covariate, and treatment and center as fixed effects.
SecondaryChange From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.

Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
baseline and 8 weeks
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
mmHgTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.-10.6 ± 1.4-2.1 ± 1.5
Statistical analysis
  • Telmisartan + HCTZ + Amlodipine vs Telmisartan + HCTZ + Placebo · LOCF-ANCOVA · p = <0.0001 (Additional information, the p-value is not adjusted for multiplicity.) · Adjusted mean, comparison: -8.6 · 95% CI -12.7 to -4.5Model includes baseline SBP as a linear covariate, and treatment and center as fixed effects.
SecondaryThe Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.

The percentage of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
Double-blind and 8 weeks
Reported as:
Number · Participants
The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.
ParticipantsTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.44.8 (32.6 to 57.4)21.9 (12.5 to 34.0)
Statistical analysis
  • Telmisartan + HCTZ + Amlodipine vs Telmisartan + HCTZ + Placebo · Regression, Logistic · p = 0.0052 (Additional information, the p-value is not adjusted for multiplicity.) · Odds ratio (or): 3.1 · 95% CI 1.4 to 7.1Exact 95 % confidence interval by Clopper and Pearson. Logistic regression includes treatment and center.
SecondaryThe Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.

The number of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
Reference baseline (week 0) and week 60 (end of extension period)
Reported as:
Number · Participants
The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.
ParticipantsTelmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + Placebo
Yes41 (32.6 to 57.4)33 (12.5 to 34.0)
No2428
SecondaryChange From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.

Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
Reference baseline (week 0) and week 60 (end of extension period)
Reported as:
Mean · mmHg
Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.
mmHgTelmisartan + HCTZ + Amlodipine + ExtTelmisartan + HCTZ + Placebo + Ext
Mean-11.4 ± 1.0-10.0 ± 1.0
Adjusted mean-10.9 ± 1.0-10.5 ± 1.0
Statistical analysis
  • Telmisartan + HCTZ + Amlodipine + Ext vs Telmisartan + HCTZ + Placebo + Ext · mixed-effects model repeated measures · Adjusted mean: -0.4 · 95% CI -3.1 to 2.3As a linear covariate, and treatment and visit, treatment by visit interaction and baseline value by visit interaction as fixed effects.
SecondaryChange From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.

Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.

Time frame:
Reference baseline (week 0) and week 60 (end of extension period)
Reported as:
Mean · mmHg
Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.
mmHgTelmisartan + HCTZ + Amlodipine + ExtTelmisartan + HCTZ + Placebo + Ext
Mean-14.8 ± 1.6-14.3 ± 1.6
Adjusted mean-13.6 ± 1.3-15.9 ± 1.4
Statistical analysis
  • Telmisartan + HCTZ + Amlodipine + Ext vs Telmisartan + HCTZ + Placebo + Ext · mixed-effects model repeated measures · Adjusted mean: 2.3 · 95% CI -1.5 to 6.1Model includes baseline SBP as a linear covariate, and treatment and visit, treatment by visit interaction and baseline value by visit interaction as fixed effects.

Adverse events

Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan + HCTZ + Amlodipine - Double Blind Period—0/68 (0%)7/68 (10.3%)
Telmisartan + HCTZ + Placebo - Double Blind Period—0/64 (0%)6/64 (9.4%)
Telmisartan + HCTZ + Amlodipine - Extension Period—2/65 (3.1%)26/65 (40%)
Telmisartan + HCTZ + Placebo - Extension Period—2/61 (3.3%)16/61 (26.2%)
Most frequent serious events
Most frequent serious events
EventTelmisartan + HCTZ + Amlodipine - Double Blind PeriodTelmisartan + HCTZ + Placebo - Double Blind PeriodTelmisartan + HCTZ + Amlodipine - Extension PeriodTelmisartan + HCTZ + Placebo - Extension Period
Large intestine polypGastrointestinal disorders0/680/640/651/61
Lacunar infarctionNervous system disorders0/680/640/651/61
Rib fractureInjury, poisoning and procedural complications0/680/641/650/61
Spinal fractureInjury, poisoning and procedural complications0/680/641/650/61
HaemothoraxRespiratory, thoracic and mediastinal disorders0/680/641/650/61
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/680/641/650/61
Deep vein thrombosisVascular disorders0/680/641/650/61
Most frequent other events
Most frequent other events
EventTelmisartan + HCTZ + Amlodipine - Double Blind PeriodTelmisartan + HCTZ + Placebo - Double Blind PeriodTelmisartan + HCTZ + Amlodipine - Extension PeriodTelmisartan + HCTZ + Placebo - Extension Period
NasopharyngitisInfections and infestations6/686/6423/6516/61
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders2/681/644/651/61

Baseline characteristics

Treated set (TS) was defined as a collection of patients i) randomised to the double-blind period; ii) taking at least 1 dose of either T80/A5/H12.5 mg or T80/H12.5 mg during the double-blind period.

Age, Continuous
Age, Continuous(Years)Telmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + PlaceboTotal
Mean56.1 ± 10.254.4 ± 7.955.2 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Telmisartan + HCTZ + AmlodipineTelmisartan + HCTZ + PlaceboTotal
Female131528
Male5549104
08

Study locations

17 sites
  • 1348.2.020 Boehringer Ingelheim Investigational Site
    Chiyoda-ku, Tokyo, Japan
  • 1348.2.008 Boehringer Ingelheim Investigational Site
    Chuo-ku, Fukuoka, Fukuoka, Japan
  • 1348.2.018 Boehringer Ingelheim Investigational Site
    Chuo-ku,Kobe, Hyogo, Japan
  • 1348.2.006 Boehringer Ingelheim Investigational Site
    Chuo-ku,Tokyo, Japan
  • 1348.2.013 Boehringer Ingelheim Investigational Site
    Chuo-ku,Tokyo, Japan
  • 1348.2.021 Boehringer Ingelheim Investigational Site
    Chuo-ku,Tokyo, Japan
  • 1348.2.012 Boehringer Ingelheim Investigational Site
    Hirakata, Osaka, Japan
  • 1348.2.011 Boehringer Ingelheim Investigational Site
    Kasaoka, Okayama, Japan
  • 1348.2.001 Boehringer Ingelheim Investigational Site
    Kawasaki, Kanagawa, Japan
  • 1348.2.019 Boehringer Ingelheim Investigational Site
    Kita-ku, Osaka-shi, Osaka, Japan
  • 1348.2.014 Boehringer Ingelheim Investigational Site
    Kiyota-ku, Sapporo-shi, Hokkaido, Japan
  • 1348.2.002 Boehringer Ingelheim Investigational Site
    Kumamoto, Kumamoto, Japan
  • 1348.2.007 Boehringer Ingelheim Investigational Site
    Nakano-ku,Tokyo, Japan
  • 1348.2.009 Boehringer Ingelheim Investigational Site
    Nishi-ku, Fukuoka, Fukuoka, Japan
  • 1348.2.005 Boehringer Ingelheim Investigational Site
    Takatsuki, Osaka, Japan
  • 1348.2.016 Boehringer Ingelheim Investigational Site
    Uji, Kyoto, Japan
  • 1348.2.010 Boehringer Ingelheim Investigational Site
    Yoshikawa, Saitama, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 2 months after primary completion. A results delay was requested in Jun 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2013
First posted
Jul 30, 2013
Start
Jul 2013
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results delay requested
Jun 25, 2014
Results first posted
Mar 28, 2016
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01911780
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Jul 2013
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Mar 28, 2016
Last update
Mar 28, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion